#62 - Keith Flaherty, M.D.: Deep dive into cancer—History of oncology, novel approaches to treatment, and the exciting and hopeful future

Episode Summary

Executive Summary: Peter Atiyah and Dr. Keith Flaherty trace cancer therapy from blunt chemotherapy and radiation to targeted therapy, immunotherapy, and liquid biopsy. They argue cancer is an evolutionary, heterogeneous disease that requires early detection, biomarker-driven treatment, and multi-drug combinations across growth, immune, metabolic, and epigenetic pillars.

Main Topics: Why the podcast is listener-supported (Priority: 4/5): Atiyah explains the decision to avoid ads in favor of subscriptions, arguing that listener support preserves trust, honesty, and independence while funding high-quality show notes, transcripts, AMAs, and member perks. Cancer as an evolutionary, systems-level disease (Priority: 5/5): Flaherty frames cancer as a process of mutation, selection, immune evasion, and epigenetic state change rather than a single-gene problem, emphasizing heterogeneity and the need to understand the frontier between known and unknown. Limits of chemotherapy, radiation, and surgery (Priority: 5/5): The discussion reviews how conventional chemotherapy mainly targets rapidly dividing cells, why radiation is locally useful but not systemic, and why surgery has reached major technical limits despite improved safety. Targeted therapy breakthroughs (Priority: 5/5): They highlight the emergence of targeted therapy through BCR-ABL in CML, HER2 in breast cancer, BRAF in melanoma, and related pathway biology (RAS/RAF/MEK/ERK, PI3K), showing how specific molecular vulnerabilities can produce durable responses. Immunotherapy and checkpoint blockade (Priority: 5/5): The conversation explains how tumors can be recognized as non-self, why melanoma and renal cell carcinoma were early immunotherapy successes, and how PD-1/PD-L1 and CTLA-4 blockade changed cancer treatment while revealing autoimmune toxicity. Liquid biopsy and early detection (Priority: 4/5): Flaherty argues circulating tumor DNA, circulating tumor cells, and exosomal markers could transform screening, minimal residual disease monitoring, and treatment selection, especially if paired with imaging and tissue-of-origin signals. Industry, academia, and translational bottlenecks (Priority: 4/5): The episode closes on the mismatch between academic discovery and commercial development, especially the difficulty of combining drugs across companies and the need for translational clinicians in biotech decision-making.

Key Arguments: Chemotherapy reached an asymptote because it was discovered by killing rapidly dividing cells indiscriminately; it works best in a narrow set of cancers such as testicular cancer and some leukemias/lymphomas. Cancer cells must evade immune surveillance, survive metabolic stress, and adapt to selective pressure; this makes them evolutionary survivors rather than simple rogue cells. Targeted therapy succeeds when a cancer is highly dependent on a specific activated driver or fusion event; CML with BCR-ABL is the classic proof of concept. Melanoma became a model for targeted therapy because BRAF mutations are common and often concentrated at a single hotspot, making the MAP kinase pathway druggable. Immunotherapy works best in tumors already visible to the immune system; melanoma and RCC were early examples because they often contain infiltrating cytotoxic T cells. Checkpoint inhibitors can produce deep, durable responses, but resistance often emerges through reduced antigen presentation and other immune-evasion programs. The future of cancer care will likely require combinations across multiple pillars: growth signaling, immune activation, metabolism, and epigenetic regulation. Liquid biopsy could enable earlier diagnosis, better risk stratification, and real-time monitoring of response or resistance, but tissue-of-origin resolution and reimbursement remain challenges. Academic medicine alone cannot solve cancer drug development; industry partnership is necessary, but current incentives make rational combination development too slow. Translational clinicians should have a stronger role in biotech and pharma governance because they understand patient-level consequences and can improve alignment between science and development.

Data Points: Podcast funding model: No ads; listener-supported subscription model - Atiyah explains the show relies on members rather than advertising to preserve trust and independence. War on cancer declaration: 1974 - Referenced as the starting point for the era being evaluated against later therapeutic progress. CML chromosomal translocation prevalence: ~95% - Most chronic myelogenous leukemia cases carry the characteristic BCR-ABL translocation. CML transplant cure rate: ~40% - Bone marrow transplant could cure a minority of CML patients before targeted therapy. Metastatic solid tumor progress from 1974 to late 1990s: Minimal; often only months of survival gain per new therapy - Used to illustrate the asymptote of conventional chemotherapy and local therapies. Melanoma mutation burden: High thousands of mutations per tumor - Flaherty notes melanoma is among the most mutated cancers, largely due to UV exposure. Functional driver mutations in melanoma: ~5-6 - Despite thousands of mutations, only a small number are thought to be functionally important. BRAF mutation frequency in all cancers: ~8% - From the 2002 Nature sequencing effort that identified BRAF as a major oncogenic driver. BRAF mutation frequency in melanoma: ~50% - Melanoma was the cancer type most enriched for BRAF mutations in the early sequencing data. RAS mutation frequency in all cancers: ~25% - Discussed as a major but historically difficult-to-drug oncogenic pathway. PI3K mutation frequency in all cancers: ~20% - Presented as another major cancer signaling/metabolic pathway. P53 mutation frequency in cancers: ~50% - Used to illustrate how often the p53 pathway is disrupted, directly or indirectly. HER2 antibody monotherapy response rate: ~10-20% - Early HER2-targeted antibodies produced modest shrinkage in metastatic breast cancer. BRAF inhibitor monotherapy survival gain in melanoma: ~9 months - Described as a major but incomplete advance in metastatic melanoma. PD-1 therapy benefit: ~10% heroic benefit; ~20% response rate - Flaherty estimates a smaller subset gets dramatic benefit, while about twice that many respond overall. Liquid biopsy tumor size threshold: Less than 1 cm - He suggests tumors below this size may still shed detectable DNA, though exact thresholds are not fully mapped. Cancer risk with age: Rises monotonically until about the ninth decade - Used to explain the inevitability of cancer with accumulating mutations and declining surveillance. Lifelong melanoma risk after diagnosis: ~10% - Flaherty cites this when counseling melanoma survivors about sun exposure and exercise. Public funding share of exploratory science: ~90% - Atiyah and Flaherty discuss the U.S. as the dominant engine for basic biomedical research. Rational combination trial pairing rate: 0.37% - Flaherty cites a paper showing how rarely promising investigational drug combinations are actually tested together.

Pivotal Quotes: "I see medicine now as this terrifying arena in which to try to assemble a multi-decade long career." — Dr. Keith Flaherty: On the challenge of staying relevant as biomedical science and oncology become more computational and fast-moving. "Chemotherapy reached an asymptote." — Peter Atiyah: Summarizing the historical limits of conventional cytotoxic cancer treatment. "We need the activators of the immune system. We need the inhibitors of the activated oncogenes. We need the drugs that target these epigenetic regulators. We need the metabolic switch regulators." — Dr. Keith Flaherty: On the multi-pillar future of cancer therapy and why single-agent approaches are insufficient.

Implications: Cancer care is moving toward earlier detection, molecular subtyping, and combination regimens. Progress will depend on better diagnostics, smarter trial design, and tighter academia-industry alignment to match therapies to tumor biology.